Patients
Everything you wanted to know
ABOUT ALLERGIES
" Have you got asthma?"
Search menu

Home and various

  • EAACI Fellowships 2015
    EAACI is pleased to announce the opening of the application period for EAACI Research and Clinical Fellowships 2015. Read more here.

  • The Allergy Awareness campaign: first wave - allergic asthma

    EAACI has launched an awareness campaign to help the society to better understand how allergy sufferers feel. The campaign will roll out through 2014-2015 and will highlight different types of allergies such as: asthma, food allergy and anaphylaxis, allergic rhinitis, allergen immunotherapy and skin allergy.

  • 34th edition of the EAACI Congress 2015 in Barcelona, 6 – 10 June 2015
    It is our pleasure to announce that registration and abstract submission is now open!  Remember to submit your abstract before 15 January 2015 at 12:00 PM CET. Take advantage of the early bird discount, register before 4 February 2015, and save up to 20% on the registration fee.
  • An Allergy School for young physicians and researchers
    Registration and Abstract submission is open for the EAACI Allergy School on "Early Diagnosis and Treatment of Allergic Diseases in Childhood" to be held in Taormina from 5 - 7 March 2015.
  • International Severe Asthma Forum 2014
    The 2nd International Severe Asthma Forum, ISAF 2014, succesfully took place in Athens, on 13-15 November 2014. Read the Press Release here to learn more on data presented during ISAF regarding innovative treatments to control and identify severe asthma.
  • 30 January - 2 February 2014, Poiana Brasov, Romania Photos
    {gallery}/photos/2014/WSBrasov{/gallery}
  • EAACI Strategic Programme 2013-15

    The mission of EAACI is to retain its core values of collegiality, inspiration and excellence. Learn about our Strategic Programme 2013-15.

  • 12th EAACI Winter School on Basic Research in Allergy and Clinical Immunology
    30 January – 2 February 2014
    Poiana Brasov, Romania


    Food allergies: from allergen to intestinal inflammation

    Eva Untersmayr
    Department of Pathophysiology and Allergy Research
    Medical University of Vienna

    Celiac Disease:Food hypersensitivity coupled with autoimmunity
    Ludvig M. Sollid
    University of Oslo

    Macrophage polarized activation in development and resolution of the inflammatory response
    Massimo Locati
    University of Milan
    Istituto Clinico Humanitas IRCCS

    Immune regulation in allergy and infection - the hygiene hypothesis in practice
    Rick Maizels
    University of Edinburgh, UK
  • EAACI Congress 2014, Copenhagen

    The EAACI Congress 2014 has been designated up to 24 hours of European CME credits (ECMEC). Take a look at the E-Preliminary Programme.
    The photo that number one in the rotating banner of http://www.eaaci2014.com/

  • Clinical Outcomes in SIT for RC
    “Recommendations for the Standardisation of Clinical Outcomes used in Allergen Immunotherapy (AIT) Trials for Allergic Rhinoconjunctivitis: an EAACI Position Paper” Pfaar O, Demoly P, Gerth van Wijk R, Bonini S, Bousquet J, Canonica GW, Durham S, Jacobsen L, Malling HJ, Moesges R, Papadopoulos NG, Rak S, Rodriguez del Rio P, Valovirta E, Wahn U, Calderon MA

    Allergen immunotherapy (AIT) has been in clinical use for more than a century. Yet it is the only immune-modifying and causal treatment available for patients suffering from IgE-mediated diseases such as allergic rhinoconjunctivitis, allergic asthma and insect sting allergy. Many modifications of this ‘causal’ treatment including e.g., alternative routes of allergen application (sublingual AIT), innovative therapy protocols or the use of adjuvanted vaccines have been reported over the years. Evidence for the clinical efficacy and good tolerability of AIT has been found in many clinical studies and is thoroughly documented in randomised controlled trials (RCTs).

    However, there is a high degree of clinical and methodological heterogeneity among the (clinical) endpoints that have been used in clinical studies on AIT, for both subcutaneous and sublingual immunotherapy (SCIT and SLIT). At present, there are no commonly-accepted (by both regulators and academia) standards for defining the optimal outcome parameters to be used for both primary and secondary endpoints. The current EMA guideline states that, at present, no symptom scores or medication scores have been validated for clinical trials in AIT and that any proposed method must be scientifically justified. As a consequence, different manufacturers are using their (‘in-house’) endpoints to analyse clinical efficacy in the clinical documentation of their products.

    In order to increase the harmonisation of this definition, a Task Force (TF) of the EAACI Immunotherapy Interest Group, chaired by Oliver Pfaar (Germany), formed a paneuropean working group. The first achievement of this TF group was a thorough review of all (primary and secondary) endpoints which have so far been reported in clinical trials on AIT. Based on this work, the TF drafted a Position Paper (PP) highlighting the pro’s and con’s of each endpoint described in the trials and, furthermore, reported clear recommendations/unmet needs to improve the usage of the respective endpoint in future clinical trials of AIT. In this PP, the nine most relevant endpoints are reported. These nine ‘domains’ include i) Total Symptom Scores (TSS), ii) Medication Scores (MS), iii) Combined Symptom Medication Scores (CSMS), iv) Health-Related Quality of Life (HRQL), v) Visual Analogue Scale (VAS), vi) Well and Severe Days, vii) Global Assessments and Patient Satisfaction, viii) Rhinitis Control and ix) Allergen Provocation Tests.

    As the primary outcome, the TF recommends a homogeneous combined symptom and medication score (CSMS) as a simple and standardised method that balances both symptoms and the need for anti-allergic medication in an equally weighted manner (table 1). In principle, this composite score is based on and modified from the “Guideline on the Clinical Development of Products for Specific Immunotherapy for the Treatment of Allergic Diseases” by the European Medicines Agency (EMA) and a draft guidance document by the US Department of Health and Human Services Food and Drug Administration (FDA). Furthermore, this score considers standards addressed in a statement as proposed by the World Allergy Organization (WAO). The proposed terminology for the individual symptoms (dSS) in this score was elaborated with the European Federation of Allergy and Airways Diseases Patients’ Associations (EFA). The EAACI Position Paper recommends this standardised and harmonised CSMS as the primary endpoint for future clinical trials in AIT (mainly in pivotal phase III-trials).

    Acknowledgements: The Task Force was financed by EAACI. The authors would like to thank EAACI for their financial support in the development of this Task Force report and also Ms Anna Bedbrook for her assistance with the English language which was financed by a grant provided by EAACI.
    We warmly thank Prof. Dr. Stefan Vieths and Dr. Susanne Kaul (Paul Ehrlich Institut, Langen, Germany) for their helpful comments. We also thank Breda Flood and Susanna Palkonen from the European Federation of Allergy and Airways Diseases Patients' Asscociation (EFA) for their advice on the proposed terminology for the individual symptoms as well as for their review and fruitful comments on this document. Additionally, we thank Simon Lawton (ALK Abello, Hørsholm, Denmark) for his critical review and comments. Table: The Task Force recommendation providing (a) a homogeneous terminology for nasal and conjunctival symptoms using the six organ-related categories in the daily symptom score (dSS), (b) a stepwise use of rescue medication summed in the daily medication score (dMS) and (c) a scoring system for a combined symptom and medication score (CSMS), which is based on an equal weight of the dSS and of the dMS

    a) SYMPTOM SCORE
    Nasal Symptoms (SCORE 0 - 3) 0 = no symptoms 1 = mild symptoms (sign/symptom clearly present, but minimal awareness; easily tolerated) 2 = moderate symptoms (definite awareness of sign/symptom that is bothersome but tolerable) 3 = severe symptoms (sign/symptom that is hard to tolerate; causes interference with activities of daily living and/or sleeping)
    Itchy nose 0-3
    Sneezing 0-3
    Runny nose 0-3
    Blocked nose 0-3
     
    Conjunctival Symptoms Itchy/Red Eyes 0-3
    Watery Eyes 0-3
     
    (total) daily symptom score (dSS)* 0-3 (max score is 3, i.e. 18 points/ divided by 6 symptoms)
     
    b) MEDICATION SCORE
    Oral and/or topical (eyes or nose) non-sedative H1 antihistamines 1
    Intranasal corticosteroids 2
    Oral corticosteroids 3
     
    (total) daily medication score (dMS) 0-3 (max score is 3)
    c) COMBINED SYMPTOM AND MEDICATION SCORE
    CSMS dSS (0-3) + dMS (0-3) 0 -6


    * Max score 18/6 (i.e. 4 nasal symptoms, max score 12 and 2 conjunctival symptoms, max score 6) is optimal for studies of seasonal pollinosis. This could possibly be modified for studies of perennial allergies (e.g. in mite-allergic patients), for example max score 12/4 (i.e. 4 nasal symptoms with omission of eye symptoms). By assigning 0–3 for all individual symptoms and dividing by total number of symptoms, the symptom range 0–3 and maximum symptom score 3 would remain the same.

    Task Force background

    Coordinator: Oliver Pfaar

    Start date: 2011
    Finish date: 2013

    Participants: Hans Jorg Malling, Jörg Kleine Tebbe, Moises Calderon, Oliver Pfaar, Pablo Rodriguez del Rio, Pascal Demoly, Roy Gerth van Wijk and Sabina Rak. The expert panel review board will comprise Desire Larenas-Linnemann, Erkka Valovirta, Gianni Passalaqua, Jean Bousquet, Linda Cox, Ludger Klimek, Marek Jutel, Stephen Durham and Tom Casale.

    Rationale for establishing a Task Force: Specific subcutaneous immunotherapy (SCIT) and specific sublingual immunotherapy (SLIT) represent the only immune-modifying and causal treatments available for allergic patients. The evidence for the effects of SIT is based on controlled and randomized clinical trials using specific primary and secondary outcome measures (end points). Primary end points for evaluating clinical outcome are the severity of symptoms and the need for concomitant medication, and are usually obtained on a daily basis by keeping diaries. Secondary end points may include the specific and general (generic) quality of life (QoL) or impact on work-related abilities, and are usually obtained by questionnaires at follow-up. Some trials have also included allergen provocation tests, provocation chambers or other surrogate markers. However, there is a large and inevitable clinical and methodological heterogeneity on outcome parameter used amongst studies on both SLIT and SCIT. The different manufacturers have devised better or less validated outcome measures, which makes it difficult to compare or to perform metaanalyses of the clinical immunotherapy trials.In line with this, in the 2008 Guideline on the Clinical Development of Products for Specific Immunotherapy for the Treatment of Allergic Diseases the European Medicines Agency (EMA) states that to date, there are no symptoms scores thoroughly validated for clinical trials on SIT. However, for the evaluation of AR the 4 individual nasal symptoms “congestion,” “sneezing,” “itching,” and “secretion,” and 2 conjunctival symptoms “itching of eyes” and “ocular secretions,” are generally accepted. Shortness of breath, cough, wheezing, and chest tightness as concomitant lower airway symptoms are also considered in some clinical trials on SIT.Moreover, there is a complex and multifactorial connection between symptom scores and the use of concomitant medication. Therefore, it is recommended by the WAO-task force on SIT that symptom scores should always be combined with the concomitant medication scores to provide clinically more relevant information on SIT than assessing each of these two outcome parameters separately. This is achievable by a combined score (weighted sum scores of symptoms and rescue medications) or a symptom score adjusted for the use of medication, using a predefined algorithm. However, to date no standardized method for combined scores has been generally accepted. Taken together, generally accepted and authoritative national and international guidelines are still lacking with respect to the assessment of the therapeutic effects of SIT by using clearly defined symptom- and medication-scores. Therefore, the aim of the task-force would be to propose a position statement clearly defining how symptoms and medications should be assessed, analysed and weighted in prospective clinical trials on SLIT and SCIT

    Main objectives: To gather present scoring-systems used in trials on SLIT and SCIT to produce an EAACI position paper on the “optimal“ (primary) outcome parameters (combined SMS) recommended for clinical research.

    Outcomes and possible benefits to EAACI: Position statement on “EAACI-recommendation for outcome parameters in clinical trials on SIT” for SLIT and SCIT.

    Updates:First meeting of this Group: MADRID 10th and 11th of March, 2012. An intense meeting with an interesting discussion was held among the following attendees: Moises Calderon, Oliver Pfaar, Pablo Rodriguez del Rio, Pascal Demoly, and Roy Gerth van Wijk. In the first session Oliver Pfaar gave a lecture based on a review of current Clinical Outcomes used in SIT trials. During the rest of the session and in the second session each outcome was critically examined and the plan of action of the team, as well as possible involvement of other experts, was established. Other meetings have been conducted in the last year, London the 2nd of June and Geneve the 18th of June 2012.
  • 2012 Allergy School: Specific Allergy and Immunotherapy, El Escorial

    15 - 17 November 2012
    El Escorial, Spain

    Evidence based VIT and sting challenge
    Carmen Moreno, Hospital Universitario Reina Sofia, Cordoba, Spain

    Handling the procedures for Food Immunotherapy
    Montserrat Fernández Rivas, Hospital Clínico San Carlos, IdISSC, Madrid, Spain
    Pablo Rodríguez del Rio, Hospital Niño Jesús, Madrid, Spain

    How to start up immunotherapy practice
    O. Pfaar
    Center for Rhinology and Allergology, Wiesbaden,
    Dept. for Otorhinolaryngology, University-Hospital
    Mannheim, Germany

    Future of immunotherapy – basic and clinical research
    Mixing of allergen: how far can we go?

    C. Pereira
    Immuno-Allergy Department
    Coimbra University Hospital Center
    Medicine Faculty, Coimbra University Coimbra - Portugal

    More presentations will be available shortly.
  • 2012 Allergy School: Asthma Exacerbations - Risk Factors and Management, Tallinn
    2 - 5 August 2012
    Tallinn, Estonia


    Anti-IgE therapy on exacerbations
    Teet Pullerits
    Dept of Allergology
    Sahlgrenska University Hospital Gothenburg, Sweden

    Asthma exacerbations as phenotype determinants in children
    Ömer Kalayci
    Hacettepe University School of Medicine
    Ankara, Turkey

    Bronchial hyperresponsiveness – techniques & result interpretations
    Svetlana Sergejeva

    Definition, epidemiology and importance of asthma exacerbations
    Antoine Magnan
    Nantes University
    Service de Pneumologie
    Nantes, France

    Do inhaled steroids prevent asthma exacerbations?
    Jonathan Grigg
    Barts and the London School of Medicine
    London, UK

    Drugs used for cardiovascular disorders and risk for asthma exacerbations
    Pascal Demoly
    Allergy Unit - Department of Pulmonology
    University Hospital of Montpellier
    Hôpital Arnaud de Villeneuve - INSERM U657
    Montpellier, France

    Environmental associates of asthma exacerbations
    Adnan Custovic
    Professor of Allergy
    University of Manchester, UK

    Industrial and urban pollution
    Jonathan Grigg
    Barts and the London School of Medicine
    London, UK

    Interactions between viruses and atopy in asthma exacerbations
    Adnan Custovic
    Professor of Allergy
    University of Manchester, UK

    Asthma: Questionnaires in real life
    Pascal Demoly
    Allergy Unit - Department of Pulmonology
    University Hospital of Montpellier
    Hôpital Arnaud de Villeneuve - INSERM U657
    Montpellier, France

    Role of asthma severity and asthma control in asthma exacerbations – implications for treatment

    Alan Altraja
    Department of Pulmonary Medicine University of Tartu
    Estonia

    Severe asthma in children
    Sejal Saglani
    Clinical Senior Lecturer Respiratory Paediatrics
    Imperial College London, UK

    The role of macrolides
    Teet Pullerits
    Dept of Allergology
    Sahlgrenska University Hospital Gothenburg, Sweden

    Treatment of asthma exacerbations in children
    Sejal Saglani
    Clinical Senior Lecturer Respiratory Paediatrics
    Imperial College London, UK

    Use of biomarkers in predicting asthma exacerbations
    Alan Altraja
    Department of Pulmonary Medicine University of Tartu
    Estonia
  • 2012 Allergy School: From Skin to Lung – From Theory to Patients, Davos
  • 2008 EAACI Congress, Barcelona
    XXVII EAACI Congress
    7 - 11 June 2008
    Bracelona, Spain



    Quality Controls in Allergy
    Alistair Crockard
    Royal Hospitals
    Belfast, Northern Ireland


    Rational application of flow cytometry in allergy
    Didier Ebo
    Immunology – Allergology – Rheumatology
    University of Antwerp, Belgium


    Tips on writing a manuscript for peer-review
    Stephen Durham
    Section Allergy and Clinical Immunology
    NHLI, Imperial College London, UK


    Co-morbidities
    Jean Bousquet
    Editor of ALLERGY
    Professor of Respiratory Medicine
    Montpellier University
    Chairman of the Global Alliance against Chronic Respiratory Diseases (GARD)


    Making most of your Abstract, Poster and Oral Presentation
    Prof AJ Frew
    Brighton & Sussex Medical School


    From 0 to 100 in 8 seconds: How to succesfully improve your career
    Prof David Gronenberg
    Institute of Occupational Medicine
    Charité – Universitätsmedizin Berlin


    How can we prevent
    Prof Ulrich Wahn
    Department of Pediatric,
    Pneumology & Immunology


    When did it start
    Prof Thomas Platts-Mills

    Why Immunotherapy Fails
    Prof Stephen Durham


Contact us

  • Contact us

    EAACI Headquarters
    Hagenholzstrasse 111
    3rd Floor
    8050 Zurich
    Switzerland
    Tel: +41 44 205 55 33
    Fax: +41 44 205 55 39

    info@eaaci.org

    EAACI – EU Liaison Office
    Rue du Luxembourg, 22-24
    B-1000 Brussels
    Belgium
    Tel : +32 (2)2 761 66 83
    EUoffice@eaaci.org

    EAACI Website
    Angel Mazon
    amazon@comv.es

    Olympia Tsilochristou
    ol.tsilochristou@allergy.gr

    EAACI Newsletter
    M. Beatrice Bilò
    MariaBeatrice.Bilo@ospedaliriuniti.marche.it

    Allergy Editorial Offices
    Professor Thomas Bieber
    Department of Dermatology and Allergy
    University of Bonn
    Sigmund Freud Str. 25
    53105 Bonn
    Germany
    Tel: +49 228 2871 4388
    E-mail: Thomas.Bieber@ukb.uni-bonn.de

    Professor Hans-Uwe Simon
    Institute of Pharmacology
    University of Bern
    Friedbuehlstrasse 49
    CH-3010 Bern
    Switzerland
    Tel: +41 31 632 3281
    E-mail: hus@pki.unibe.ch


    Pediatric Allergy and Immunology Editorial Office
    Professor Ulrich Wahn, Editor-in-Chief
    Dept of Paediatric Pneumology and Immunology
    Charite Medical School
    Virchow Klinikum Campus
    Augustenburger Platz, 1
    13353 Berlin
    Germany
    E-mail: Doris Kollmann, Assistant Editor
    paieditorial@charite.de

Tab Articles

    Archive

    • EAACI Treasurer

      Marek Kowalski

    • Treatment can lead you to gold!

      Athletes who suffer from asthma or allergies and are about to participate in the 2008 Beijing Olympic Games, have the same chances for success with athletes that are not facing the same problem.

    • Mediterranean diet may protect kids from hay fever

      1807A Mediterranean-type diet may protect children from developing asthma and allergic rhinitis, which is largely known as hay fever.

      A recent research published in Allergy Journal, the official Journal of the EAACI, reports on the evidence of the additional benefits of healthy dietary habits to a healthy diet among children. Diet during pregnancy and childhood is thought to play an important role in children's asthma risk. In the current study, researchers examined the association between both children's diet and their mother's diet during pregnancy and the development of asthma and allergic rhinitis in a random sample of 1,476 children aged 6 to 7 years old.

      Among children, greater adherence in the previous year to a Mediterranean diet that it was high in vegetables, fruits and nuts, legumes, fish and cereals and low in dairy products, meat, junk food and fat, was associated with less asthma, wheezing, allergic rhinitis, sneezing and itchy-watery eyes.

      The researchers did not find an association between consumption of a Mediterranean diet during pregnancy and reduced risk of asthma or allergic rhinitis in children.

      According to the researchers, the suggestion that a Mediterranean diet may protect against asthma is biologically plausible. This type of diet is rich in antioxidants that may protect the lung and airway from oxidative damage. It is also rich in fish, a good source of omega-3 fatty acids and light in omega-6 fatty acids. This ratio of omega-3 to omega-6 fatty acids has been shown to reduce harmful levels of pro-inflammatory proteins, which are often increased in asthma sufferers.

      Source
      ALLERGY Journal, September 2008

    • Treatment can lead athletes to high achievements and safeguard fair competition

      Just a few months ahead of the Beijing 2008 Olympic Games and the European Football Cup, top experts on Allergy and Asthma from Europe and the US, gathered in Barcelona, in order to evaluate and talk on the dangers as well as the possibilities of athletes

    • Hospitals Put Allergy Patients at Risk
      Patients are being put at risk because some hospital doctors are not always following warning procedures over known drug allergies
    • Link between paracetamol use and asthma in European adults

      A link between paracetamol use and asthma in European adults was confirmed in GA²LEN study.

    • Allergies, Asthma and Wealth
      Children in richer nations are more likely to have allergy-related asthma than their counterparts in poorer nations
    • Transnational Research on the topic of allergic rhinitis

      A survey carried out by scientists in Germany, France, Italy, Spain and the U.K

       

       

    • Parental-reported drug allergy in 6- to 9-year-old urban schoolchildren

      Review article on epidemiologic studies about the prevalence of adverse drug reactions in children are scarce compared to reports in adults.

       

    • Food allergy prevention and management Asthma and Immunology

      Important research findings may impact diet restrictions of food allergic patients.

       

       

    • Whole Grains and Fish May Decrease Asthma Risk in Children

      A recent study in Dutch children has found that increasing intakes of fish and whole grains may help with asthma, especially in children.

       

    • XXVII EAACI Congress in Barcelona

      Under the slogan “Clinical Features of Allergy: From Pediatrics to Geriatrics” the XXVII EAACI Congress is up and running in Barcelona, the capital of Catalonia, from 07-11 June 2008.

    • World Asthma Day May 6th / Beijing Olympic Games

      Asthma & Sports: a mighty co-existence

    • Sport and asthma: GA²LEN researchers follow European Olympic athletes to Beijing

      Ten centres of GA²LEN will be following athletes selected for the Olympic Games 2008 to assess the prevalence and diagnosis rates of asthma and allergies.

    • Individualised treatments are the only efficient way to tackle with asthma

      Individualised treatments are the only efficient way to halt asthma`s advance.

       

    • NHS fails children with eczema

      Children with eczema in the UK are not getting the medical treatment they deserve as their parents use herbal medicines that may sometimes do more harm than good.

       

    • Europe and US together against childhood asthma

      The two major scientific organizations in the field of asthma, EAACI and AAAAI have reached consensus on optimal strategies to tackle asthma in childhood.

    • Announcement IPAC

      18 and 20 October 2007 Guincho, Portugal

    • Seasonal allergy in Texas

      The upcoming fall season could be the worst in decades for allergic people in Texas

    Static

      Disclaimer

      • EAACI WEB DISCLAIMER
        All materials provided by this Web site are intended for educational, communication and information purposes only and are not intended to replace or constitute medical advice or treatments.

        The EAACI intends that the information contained in this site to be accurate. Public education and information materials contained in this site have been reviewed and approved by the site's web editors or the EAACI Web Management Committee. However, due to error occurrence, EAACI disclaims any warranty of any kind, whether express or implied, as to any matter whatsoever relating to this servsiice. Under no circumstances, shall the EAACI be liable for any indirect, special, incidental or consequential damages arising out of reliance on any content of the web site contained herein.

        EAACI does not assume and hereby disclaims any and all liability to an entity for any claims, damages, liability or other loss including, without limitation, any liability for damage resulting from reliance on this service or from the posting of any content or material by any third party. No material included in this site shall be deemed to present necessarily the best method or procedure with respect to a matter discussed on this service; rather, any such material shall be acknowledged as the approach or opinion of the discussant.

        PRIVACY POLICY

        Privacy policy for the websites of the European Academy of Allergy and Clinical Immunology (EAACI)
        EAACI is committed to protecting your online privacy. This policy governs all pages hosted by EAACI, including the Allergynews.com website and any other website it will create in the future. It does not apply to pages hosted by other organisations, including National Societies of Allergy and Clinical Immunology, which have their own privacy policies.

        EAACI uses the information it collects about you to better understand how its website is used, to send information on EAACI you have requested or that may be considered of interest to you, to process your membership application and to render services you have ordered or which are included in your membership.

        To understand how your personal information will be treated, please read the following policy. This policy may change from time to time so please refer to it periodically.

        What identifiable information is collected from you?
        The type and amount of information received and stored by EAACI depends on how you use the website. You can access most EAACI pages without stating who you are and without revealing any personal information, except in the case of online membership applications or in the case you want to access the "Members Only Area" of the website.

        EAACI does not collect information identifying you personally (such as your name, address, phone number or e-mail address) unless that information is voluntarily disclosed. There are instances where EAACI requests information that does identify you personally for the purpose of providing you with specific services or of corresponding with you. Information that you supply in this way will not be shared with any third party except where needed to provide a requested service or required by law.

        How does EAACI use the information?
        EAACI does not distribute, sell or rent user information to anyone. EAACI uses the information collected about you to improve its understanding of web visitors, to send information that you have requested or that may be considered of interest to you, to process your membership application and to render services you've ordered or which are included in your membership. Some information identifying EAACI members is forwarded to third parties for purely technical and administrative processing (e.g. to Wiley Publishing to send out Allergy and Pediatric Allergy and Immunology (PAI) and the Newsletter). These parties are not authorized to distribute, sell or rent user information.

        With whom may EAACI share the information?
        EAACI will not disclose any information identifying you personally, except with your prior permission or where required by law.

        What choices are available to you regarding collection, use and distribution of the information?
        Any information on new EAACI products that you registered to receive will be sent to you electronically or by other means. EAACI may also send you unsolicited e-mail messages it feels may be of interest to you. You can indicate that you do not wish to receive the mail messages by sending an e-mail to info@eaaci.org and you will be removed from the recipients' list.

        How can you access, update or delete the information?
        EAACI takes very seriously the accuracy of the information it holds on you. If you change your e-mail address or discover inaccurate information, or if you wish to unsubscribe, please send an e-mail message to info@eaaci.org. Members are invited to regularly update their profile in the "Members Only Area" of the website.

        How does EAACI treat your personal information?
        EAACI ensures to the best of its ability that any personal information you provide is secure on its systems. However, it cannot guarantee that submitting information over the Internet is 100% secure. As a result, EAACI does not confirm or warrant the security of personal information submitted; you do so at your own risk.

        Automatically collected information

        Cookies

        Like many other websites, the EAACI site uses cookies in order to provide you with a more personalised web experience.

        A cookie is a text-only string of information that is created and stored on your computer by your browser. It contains information about your visit that your browser uses to personalise certain pages or elements. For statistical analysis purposes, a cookie may also be used to pass a randomly generated and anonymous unique number to our servers. Cookies cannot be used by themselves to identify you. A cookie will typically contain the name of the domain from which the cookie has come, the "lifetime" of the cookie, and a value, usually a text value or a randomly generated unique number.

        If you do not wish to receive cookies, you can easily modify your browser to reject all cookies or to notify you whenever one is about to be placed on your computer. However, if cookies are not accepted you may not be able to use all the interactive features of the EAACI website. You are therefore encouraged to allow cookies in order to enjoy the EAACI site fully.

        Log files

        Most standard web servers, including EAACI's, use log files, which record information such as:

        • service provider IP addresses;
        • browser versions;
        • referring web sites;
        • search terms used;
        • average number of pages requested;
        • average duration of visit;
        • total visitor traffic;
        • information gathered for aggregate use.

        Disclaimer

        This site contains hypertext links to other sites. EAACI is not responsible for the content or privacy practices of external websites.


        PROPRIETARY NOTICES

        "THE EUROPEAN ACADEMY OF ALLERGOLOGY AND CLINICAL IMMUNOLOGY", "EAACI", and the EAACI logo are trademarks of The European Academy of Allergology and Clinical Immunology. Use of these marks in commerce is prohibited by law except by obtaining the expressed written permission of the EAACI Web Committee.

        Copyrights to the materials posted in this site are owned solely by the EAACI, except for materials which are created by others (or the copyright to which is otherwise owned by others) and for which a copyright notice is posted adjacent to such content or materials. The copyright to each item of material created or otherwise owned by another is owned by such creator or other owner. None of the materials included in this site shall be reproduced in any form without the expressed written permission of the EAACI, the creator or other owner, as the case may be. In this regard, the graphic images and layout of this site are the exclusive property of the EAACI and may not be copied, distributed or displayed except using an HTML browser or as otherwise stated herein, without the expressed written permission of the EAACI Web Committee.

        Permission is hereby granted to (1) print copies of the materials for which the EAACI holds the copyright ("EAACI content") and to otherwise display the EAACI content, (2) include a link to the Uniform Resource Locator (URL) of this site to HTML documents, and (3) to use the EAACI content subject to the following conditions:
        Such use is by computer using HTML browser software; Such use is solely for personal and noncommercial use and only for informational and/or educational purposes; Users shall not make any profit from the EAACI material in any way (i.e., by selling or charging for same) unless the expressed written permission of the EAACI is first obtained;

        Any copying or quoting of the EAACI content shall be accompanied by the following copyright notice: "© Copyright 2008 The European Academy of Allergology and Clinical Immunology. All rights reserved."

        Except as stated herein, no portion of the materials included in this site may be reproduced or transmitted in any form by any means, whether by electronic, photocopying, recording or otherwise, without the written permission of the EAACI.

        Address inquiries regarding the use of the EAACI trademarks, logos and copyrights or the trademarks, logos and copyrights of third parties which are contained in this site to:

        EAACI Headquarters
        Hagenholzstrasse 111
        3rd Floor
        8050 Zurich
        Switzerland
        Telephone: +41 44 205 55 33
        Fax: +41 44 205 55 39 P.O. Box 24140
        Email:info@eaaci.org


        EAACI RESOURCES

        Disclaimer and Proprietary Notices
        This service is intended for use only by medical professionals and academics. The materials and other information provided by this service are for general educational, communication and information purposes only and are neither designed nor intended to replace nor constitute the giving of case specific or other medical advice, treatments or diagnosis. Under no circumstances shall any information, content or material posted on this service or any other communication thereunder be deemed to constitute the giving of medical advice, treatment or diagnosis. The user of this service shall be solely responsible for whether or how to interpret, apply or otherwise use any information in any specific case.

        No information cited under Resources shall be deemed to present the only or necessarily the best method or procedure with respect to a matter discussed on this service; rather, the user acknowledges that any such information or material is acknowledged as the approach or opinion of the discussant. The user takes all risks of using the material included in this service.

        EAACI does not assume and it hereby disclaims any and all liability to any person or entity for any claims, damages, liability or other loss including, without limitation, any liability for injury or other damage resulting from reliance on this service or from the posting or transmission of any information, content or material on this service by EAACI, or any third party. By using this service the user releases EAACI and its directors, officers, members, or agents from and against any and all such liability.



        EAACI WEBCASTS

        Disclaimer and Proprietary Notices
        By viewing the EAACI Web Casts, the user agrees to the following terms ("Terms") governing use of the Web Casts, plus any additional terms and conditions posted at specific portions of the web site. Access to the Web Casts and all related pages is conditioned upon the user's acceptance of the following terms:
        Access. The EAACI grants all users to a non-exclusive, revocable license to use the materials and information on the Web Casts solely for professional practice in accordance with the Terms herein. All users are responsible for their acts or omissions in the use of the Web Casts and for any damages incurred by them or anyone else as a result thereof.
        Purpose. The Web Casts and their content are being provided for educational and informational purposes only, and are not intended to be a substitute for an independent medical judgment or constitute medical advice or treatment in any way. The content posted on the Web Casts is not intended to serve as the primary basis for making professional medical decisions. As with all clinical reference resources, the content on the Web Casts reflects medical science, protocols and/or procedures at the time of its development, but the content should be used with the clear understanding that continued research or practice may result in new knowledge or recommendations. Therefore, all users should cross check the information given in the Web Casts with other sources before undertaking any treatment or otherwise taking any actions related to or in reliance on such information. The user's reliance upon any content within the Web Casts is solely at their own risk.
        Damages. Under no circumstances will EAACI be responsible or liable for any damages of any kind or nature that result, or relate in any way to the use of this site or any content herein, including, without limitation, any compensatory, indirect, incidental, consequential, damages.


        PHOTOS, GRAPHICS & TEMPLATES

        To visually demonstrate the physiology of allergic diseases and asthma in Europe and/or support any material posted in the web site, the EAACI has developed allergy and asthma graphics and templates which may serve as visuals to compliment the speaker's presentation in the EAACI meetings. For use of any of the above features, kindly attribute all images as follows:

        "Source: The European Academy of Allergology and Clinical Immunology."

      E-Bulletin

        Media

          Activities

            Organisation

              sections

                Juniors

                Resources

                  IGs

                  • Introduction
                    M. van HageWithin the EAACI, Sections and Interest Groups are structural units that facilitate various Academy functions and activities.

                    Diseases mediated by allergic and immunological mechanisms can affect many different organs and may present problems to a wide variety of physicians in primary and secondary care. In order to improve information exchange and collaboration between specialists and scientists both within and outside the EAACI, the Academy has established the EAACI Sections for Asthma, Dermatology, ENT, Immunology and Pediatrics.

                    The sections are represented in the Executive Committee and Programme Committee, and have the opportunity to propose task forces as well as joint sessions with appropriate specialists societies.

                    The Interest Groups represent an area of general interest within allergology that is not adequate covered by any one of the EAACI Sections. Additionally, Interest Groups provide a focus for scientists and clinicians interested in particular aspects of allergic diseases. At present, there are Interest Groups active for Aerobiology & Pollution, Allergy Asthma & Sports, Allergy Diagnosis, Allied Health, BiologicalsComparative and Veterinary Allergology, Drug AllergyEpidemiology, Food Allergy, Functional Genomics and Proteomics, Immunotherapy, Immunodeficiency, Infection & Allergy, Insect Venom Hypersensitivity, Occupational Allergy, Ocular Allergy, Primary Care and Primary Immunodeficiency.

                    The Interest Group forms a focus for discussion at the Academy's meetings, provides input to the scientific programme, and can make proposals for the task forces. All members and affiliates (including "Juniors") are encouraged to take part in the EAACI Interest Groups.

                    All EAACI members are welcome to sign up as a member, with a voting right in one of the Sections or Interest Groups. However, as an EAACI member, you are welcome to take part in the activities of as many Sections and IGs as you like.

                  Homepage Deadlines

                  Homepage Congresses

                  Outreach

                    Upcoming events

                    Updates

                    • Find EAACI in Social Media
                      Want to keep up to date with all EAACI news and deadlines?
                      Why not follow us on Twitter and Instagram, like our page on Facebook or find us on LinkedIn and Google Plus? You can also post your photos from EAACI events as well as your views and opinions on a range of topics
                    • Reducing the incidence of food allergy in children

                      Dublin, Ireland, 9 October 2014

                      The frequency of food allergic reactions is greater among children than among adults and up to 17% of the European population may be affected. During FAAM 2014 that took place in October, in Dublin two new studies focusing on the prevention of allergy in children were presented. Read more in the Press Release here, also available in Spanish.
                    • Faster and accurate identification of drugs causing allergic reactions: a great relief for patients

                      Krakow (Poland), 18 September 2014

                      Cutaneous adverse drug reactions: Diagnosis of CADR could now improve significantly thanks to a new method developed by a group of researchers led by Dr Grzegorz Porebski, Jagiellonian University, Department of Clinical and Environmental Allergology (Krakow, Poland). Read more in the Press Release here.

                    • Up to 22% of European children have an allergy, with serious reaction to food on the rise

                      Zurich, Switzerland 07.04.2014

                      – Anaphylaxis is increasingly found in allergic reactions in children, primarily caused by food allergies in this population group: up to 22% of European children have an allergy, with serious reaction to food on the rise1. The severity of its effects, which can be fatal, demands the attention not only of allergologists but of all healthcare professionals. This is one of the most important messages found in advance of the new guidelines on anaphylaxis on which the European Academy of Allergy and Clinical Immunology (EAACI) is currently working.

                      Read more here and the press release here.
                    • More than 7% of the general population are affected by drug allergy reactions, involving excessive cost for the healthcare system
                      Berne (Switzerland), April 14th 2014 – Drug Hypersensitivity Reactions (DHRs) affect 7% of the general population and represent a major health problem, as they can be life-threatening and require or prolong hospitalisation. Furthermore, both underdiagnosis (as they are insufficiently detected) and overdiagnosis (due to excessive use of the term “allergy”) are common in clinical practice, and this can lead to the prescription of more expensive or less effective drugs.

                      To find out more, click here. Also available in French and German.
                    • 9 out of 10 people die of a chronic disease in Europe
                      EAACI was proud to join the European Chronic Disease Alliance (ECDA) at the first EU Summit on Chronic Diseases in Brussels from April 3-4. ECDA welcomed the Commission’s initiative to organise the Summit, which we hope to be a step towards an EU framework to allow the EU to make a significant impact in reaching the United Nations goal of a 25% reduction in premature mortality from chronic diseases by 2025.
                    • Go Green with EAACI
                      Reflecting the feedback from our recent Membership Benefits Survey we are asking you to "Go green with EAACI" and offering the possibility to opt out from receiving printed versions of Allergy and/or Pediatric Allergy and Immunology by selecting the opt out box(es) at the Membership Profile Management Page.
                    • EAACI Fellowship 2014 Awardees
                      EAACI is proud to announce the awardees of the 2014 Fellowships, to support highly skilled specialists in this field in Europe, intended for EAACI members in training for allergy and clinical immunology early in their careers.
                    • Allergy School Presentations Slides for EAACI Members
                      The presentation slides of the Allergy Schools in Poiana-Braslow and in Newcastle,upon-Tyne are now online, available only for members. Login to the Members Area and access the presentations!
                    • 178 Members of the European Parliament call for coordinated European action on allergies
                      In October 2013, eleven members of the European Parliament (MEPs) proposed a draft Written Declaration on recognising the burden of allergic disease. At the end of the consultation period, the Declaration was supported by a total of 178 MEPs.
                    • PAAM: Pediatric Allergy and Asthma Meeting, Athens 2013
                      The third Pediatric Allergy and Asthma Meeting (PAAM) was held in Athens on 17 - 19 October 2013. PAAM 2013 scientific programme is a cutting edge line-up that covers all major areas in the field (including anaphylaxis, food allergy, asthma, rhinitis, eczema, and immunotherapy) as well as more rare conditions.

                    Questions Patients

                    Uncategorized

                    • test chris 2
                      {gallery}photos/2014/WSBrasov/{/gallery}
                    • Past Task Forces
                      -. Task Force on “Standardization of (Primary) Clinical Outcomes for Clinical Trials in AIT

                      TF-Coordinators: Oliver Pfaar and Sabina Rak

                      Start-date: 2011, current status: ongoing

                      Rationale: Generally accepted and authoritative national and international guidelines are still lacking with respect to the assessment of the therapeutic effects of AIT by using clearly-defined symptom- and medication-scores. Therefore, the aim of the task-force will be to propose a position statement clearly defining how symptoms and medications should be assessed, analyzed and adequately weighted in prospective clinical trials on both SLIT and SCIT. Current status: EAACI-Position Paper in progress

                      -. Project "Semantics in SIT and MedDRA terminology for adverse reactions due to SIT" Coordinator: Pascal Demoly and Moises Calderon

                      Start date: 2011

                      Finish date: 2012

                      Rationale: Current semantic use to characterize allergen immunotherapy and terminology for adverse reactions is heterogeneous depending on the countries and/or the scientific societies.

                      Main objective:
                      To create a common language for all audiences regarding immunotherapy and identify semantic keys to reinforce the impact of communication on allergy immunotherapy. To create a harmonised MedDRA based terminology for the report of adverse reactions after SIT in a real life setting.

                      -. Task force on “Contraindications for AIT

                      Coordinator:
                      Constantinos Pitsios

                      Start date: 2011

                      Finish date: 2013

                      Rationale: Despite the large number of papers published on SCIT and SLIT, there is still no common agreement on the “contra-indications” for SIT.

                      Main objective: To collect and compare clinical data on the effect of Allergen Immunotherapy on conditions and diseases that are currently considered as contraindications.
                      A systematic literature search has been performed to re-assess AIT contraindications and adapt them to the current situation of different diseases, co-morbidities and certain drugs. Current status: A Consensus Meeting has taken place on May 2013 and the Task Force Report - Position paper is in progress. An international survey (CONSIT) regarding the opinion of allergologists on AIT's contraindications has been performed and is soon going to be published.

                    • rtest6
                      test6333 rer testet testtt asdasd sdsdf
                    • test5
                      test5
                    • Not Found

                      Page Not Found :(

                      Sorry, but the page you were trying to view does not exist.

                      Please use the sitemap in case you can not find what you are looking for

                    Image Gallery

                    Allergy Schools Travel Grants

                    • Allergy School on Allergy Diagnosis in and beyond the skin - Travel Grant Winners
                      Pavel Kolkhir
                      Abstract 2426960
                      Autologous Serum Skin Test And Autoimmune Biomarkers In Diagnosis Of Chronic Spontaneous Urticarial”

                      Juan Manuel Leyva-Castillo
                      Abstract 2424046
                      Innate and adaptive recruitment of basophils in a thymic stromal lymphopoietin-induced atopic dermatitis mouse model
                    • Allergy School on Allergic Reactions to Drugs – From Phenotype to Genotype - Travel Grant Winners
                      Katinka Onodi-Nagy
                      Abstract 2393415
                      In Vitro And In Vivo Investigation Of Amoxicillin-Induced Exanthema In Patients With Infectious Mononucleosis

                      Semra Demýr
                      Abstract 2439644
                      Clinical Analysis Of Nonsteroid Antiinflamatory Drugs Hypersensitive Patients: Atopy May Increase The Risk Of Additional Drug Allergy

                      Nicolae Viorel Dumitrescu
                      Abstract 2441445
                      Research On Nsaids Types Involved In Hypersensitivity Reactions And The Safety Profile Of The Cox-2 Selective Nsaids In Patients With Chronic Urticarial
                    • Allergy School on The place of "omics" in the diagnostic lab: Update on Allergy & Clinical - Travel Grant Winners
                      Shanna Bastiaan-Net
                      Abstract 2390583
                      Differential Allergy To Prawn And Shrimp: A Case Of Epitope Specificity Or Difference In Allergens?

                      Ewa Pniewska
                      Abstract 2429013
                      Taqman Low Density Array Cards As A Tool For Searching The Expression Profile Of Genes Involved In Airway Inflammatory Diseases

                      Jan Remsik
                      Abstract 2390353
                      Changes In Th1/Th2 Ratio After Built-Up Phase Of Subcutaneous Allergen-Specific Immunotherapy”

                      Dorota Kacprzak
                      Abstract 2429633
                      Microarray Studies As A Useful Tool For Identifying Genes Involved In Aspirin-Induced Asthma
                    • Allergy School on Hymenoptera Venom - Travel Grant Winners
                      Süleyman Tolga Yavuz
                      Abstract 2283769
                      Risk Factors For Side Effects During Venom Immunotherapy In Children With Hymenoptera Venom Allergy

                      Martina Vachova
                      Abstract 2303869
                      Laboratory parameters in hymenoptera venom allergic patients during venom immunotherapy - 6 years study

                      Dimitrios Mitsias
                      Abstract 2305429
                      Sting challenge proves the effectiveness of 50ìg dose in honey bee venom immunotherapy

                      Ines Schwarz
                      Abstract 2307491
                      Does the sting localization play a role for the severity of symptoms in hymenoptera venom allergy?

                      Danijela Bokanovic
                      Abstract 2307520
                      Negative predictive value of the basophil activation test in hymenoptera venom allergy

                      Christoforos Koulias
                      Abstract 2314912
                      A modified rush venom immunotherapy protocol for subjects with underlying mast cell disease
                    • Investigating allergic effects of environmental exposures - winners

                      Travel Grant and Poster Prize winners

                      Marta da Fonseca Gabriel, Spain
                      Abstract title: Development Of A Phylogeny And Gene Encoding-based Tool For Detection Of Alt A 1 Allergen

                      Teresa Stemeseder, Austria
                      Abstract title: IgE Profiling Of 378 Non-selected Austrian School Children And Investigation Of Their Lifestyle

                      Poster prize winner
                      Peter Gajdos, Czech Republic
                      Abstract title: Upper Respiratory Infections And Allergic Diseases In Ostrava

                      Oral abstract prize winner
                      Richard Sanya, Uganda
                      Abstract title: Associations Between Helminth Infections And Atopy And Allergy-related Diseases In Island Communities In Uganda: Baseline Findings Of The Lake Victoria Island Intervention Study On Worms And Allergy
                    • Allergy School on An Insight into Allergy and Allergen Immunotherapy - winners

                      Travel Grant and Poster Prize winners

                      Heidi Hofer, Austria
                      Abstract title: MBC4: A hypoallergenic variant for treatment of birch pollen and associated food allergies towards apple and hazelnut

                      Elena Kasche, Germany
                      Abstract title: Immunogenicity, induction of allergen tolerance, safety, and clinical tolerability of increasing doses of GpASIT+TM administered subcutaneously to hay fever patients

                      Alkerta Ibranji, Albania
                      Abstract title: The role of allergy immunotherapy on asthma control in teenagers sensitized to house dust mites

                      Sandra Viviana Olariu, Romania
                      Abstract title: An unusual case associating meningioma and rare side effects to sublingual immunotherapy

                      Gjustina Loloci, Albania
                      Abstract title: Systemic adverse events a rare reaction to sublingual immunotherapy: A case report

                      Pablo Rodriguez Del Rio, Greece
                      Abstract title: Using AIT despite contraindications; CONtraindications to Specific ImmunoTherapy (CONSIT) Study

                      Laura Hesse, Netherlands
                      Abstract title: Subcutaneous and sublingual immunotherapy effectively suppress asthma manifestations in a mouse model of grass-pollen induced allergic asthma

                      Huan Zhang, Sweden
                      Abstract title: Sublingual immunotherapy alters expression of IL-4 and its soluble and membrane-bound receptors”

                    Juniors AboutUs

                    • About Us

                      The Junior Member and Affiliates (JMAs) constitute the largest section of EAACI, currently with 3210 members. Working towards their best interest, the JMA Working Group (JMA WG) is formed by one JMA Representative from each EAACI Section and Interest Group as well as by our Webmaster and myself, as the Chairperson. Having one representative from each section and IG confers a unique dynamic to the JMA section and allows us to be naturally involved in all initiatives of the Academy. Capitalizing on this unique structure and supported by EAACI's leadership, the JMA Working Group aims to address the needs and to facilitate the development of young clinicians and scientists who devote their careers to the field of Allergy and Clinical Immunology.

                      In 2013-2015, the JMA WG aims to:

                      • enhance education in the field of Allergy and Clinical Immunology and the participation of JMAs in EAACI Allergy Schools and other educational activities;
                      • promote and coordinate the EAACI Mentorship Program;
                      • encourage JMAs to apply to EAACI Fellowships;
                      • increase the number of JMAs taking the EAACI knowledge exam;
                      • facilitate an effective communication among JMA and between JMA and senior members of EAACI;
                      • promote the collaboration of JMAs with EAACI journals;
                      • organise JMA-dedicated sessions and facilitate the involvement of JMAs in EAACI Congress and Focused Meetings as attendees and as faculty members;
                      • disseminate information about EAACI and Allergy and Clinical Immunology, particularly that of special interest to JMAs, via eaaci.org, EAACI Newsletter, facebook, twitter, linkedin and other social media;
                      • collaborate with other international and national Allergy societies.

                      Step by step, with growing enthusiasm and dedication to the field of Allergy and Clinical Immunology, JMAs are the future of the Academy!

                      Alexandra Santos
                      JMA Chair

                    • Becoming a JMA
                      The JMA Membership fee is FREE and includes on-line access to the three EAACI Journals (Allergy, Pediatric Allergy and Immunology and Clinical and Translational Allergy.

                      JMAs are eligible for Fellowship and Travel Grants to attend the EAACI Annual Congress, Allergy Schools and Focused Meetings.

                      The JMA Committee is formed by a JMA Chair, who is a member of the Executive Committee, a JMA Webmaster and one JMA representative in each EAACI Section. All interested JMAs are welcome to work with the group and to apply for one of the posts when available. If you are under 36 years old and interested in the field of Allergy and Clinical Immunology, read more here and contact the EAACI Headquarters to become a member.

                      EAACI Headquarters
                      Hagenholzstrasse 111
                      3rd Floor
                      8050 Zurich
                      Switzerland
                      Telephone: +41 44 205 55 33
                      Fax: +41 44 205 55 39
                      info@eaaci.org
                    • News

                    Website past committies

                    Juniors Past Boards

                    Juniors Minutes of Business Meetings

                    Juniors Activities

                    • JMA Activities
                      JMAs are actively involved in a series of activities including Section Activities, Allergy Schools, as well as Business Meetings. JMAs operate their own schedule and programme at all EAACI Congresses, which apart from scientific meetings involve several social activities that help Junior Members of the Academy get to know each other better in a more relaxed environment.

                      During the last years, EAACI has developed specific activities and promotions to support and to increase the influence of the younger members. Many travel grants are available for JMAs to attend the EAACI Annual Congresses and several JMA activities are arranged:

                      - JMA Poster Session, which is an informal session aimed to promote the work of JMAs and to facilitate contacts between EAACI members. Outstanding poster presentations are awarded poster prizes.

                      - JMA Scientific Symposium which is a main session on a hot topic, chaired and organised by JMAs.

                      - JMA educational session were practical topics such as how to write a paper, how to give a presentation... are covered.

                      - JMA Case reports session were selected clinical cases are presented by JMAs. Outstanding case presentations are awarded case report prizes.

                      - Practical courses which are co-chaired by one Senior EAACI member and one JMA and address practical themes of great interest to JMAs.

                      - JMA Business Meeting where JMAs meet and discuss present and future.
                    • JMA-PAI collaboration
                      Dear JMAs,

                      A collaboration between the JMA and the Pediatric Allergy & Immunology (PAI) journal was launched at the EAACI Annual Congress in Istanbul in June 2011.

                      JMA PAI  Milan 2013

                      Since then, the JMAs have worked closely with the Editorial Office of PAI to develop new initiatives to promote the journal and related educational activities.

                      Announcement and promotion

                      The JMA-PAI Collaboration was announced and has been promoted through both www.eaaci.or, the Wiley website as well as through EAACI’s promotional flyers. The JMAs have also created a Facebook page dedicated to the PAI journal where information relevant to the publication and to JMAs is regularly posted. Come and find us on Facebook!

                      National Research Networks

                      As part of the JMA-PAI Collaboration, a pilot-project was developed with the Italian Society of Pediatric Allergy and Clinical Immunology (SIAIP) in order to involve more JMAs in the project and to distribute the journal’s content at national level in Italian. This initiative was also supported by the existing and active Junior Group of the Italian Society of Allergy and Clinical Immunology (SIAIC) and it is now set to be extended to other European countries.

                      "10 years of JMA" Anniversary Paper

                      A paper has also been published in PAI authored by the JMA Working Group to celebrate the 10-year anniversary of the EAACI-JMAs. You can read it here!

                      JMA Hot Topic Reviews

                      Junior members of our Academy were given the opportunity to submit “hot topic reviews” in cooperation with their mentors for publication in the PAI journal. Two papers have now been accepted and published as part of this initiative:

                      1. Alexandra Santos & Gideon Lack
                      Santos AF, Lack G. Food allergy and anaphylaxis in pediatrics: update 2010–2012. Pediatr Allergy Immunol 2012: 23: 698–706.

                      2. Laura Hatzler & Nikos Papadopoulos
                      Hatzler L, Hofmaier S, Papadopoulos NG. Allergic airway diseases in childhood – marching from epidemiology to novel concepts of prevention. Pediatr Allergy Immunol 2012: 23:616–622.

                      JMAs as Peer-Reviewers

                      JMAs who are active in their research field have been suggested as reviewers for PAI and the editors have expressed their happiness with their contributions which were prompt and very relevant. This has led to JMAs suggesting colleagues who could potentially be added to the PAI database of reviewers.

                      Do not miss the opportunity to express your interest in serving as a reviewer for this journal or to suggest other JMA colleagues! If interested please email a short CV along with a statement of interest and/or your proposals for other possible reviewers to jma@eaaci.org.

                      JMA must-read papers

                      In every issue of PAI, the JMA-PAI collaborative team has selected the paper that is most relevant to fellows in training for its educational content. The JMA must-read papers are highlighted with the JMA logo in both the printed and the online version of the journal.

                      The abstracts of the JMA-must read papers have been translated into 15 different languages to help spread their important messages across numerous countries. We would like to thank all the JMAs who kindly collaborated with us in translating these abstracts.

                      Webcasts

                      The JMA-PAI collaborative team is now working on a new initiative to create additional educational material from papers published in PAI. As a pilot-project, a position paper on allergy diagnosis in children is now being turned into a webcast and additional papers will follow this format. We look forward to sharing them shortly!

                      With our best regards,
                      The JMA-PAI collaborative team



                      Chrysanthi Skevaki, Alexandra Santos, Paraskevi Maggina, Enrico Heffler (JMA)
                      Ulrich Wahn, Paolo Matricardi, Doris Kollmann, Laura Hatzler (PAI)

                      Translators of the abstracts of JMA-must read articles Pediatric Allergy and Immunology
                    • JMA-Allergy collaboration
                      Dear JMAs,
                      As you might know there is an established collaboration between Allergy Journal and JMAs starting from last year. Already under the JMA Reviews issue articles like ''T cell tolerance in allergic response'' by K. Blaser, ''Up-date on chemokines and chemokines' receptors'' by A.Mantovani and '' Difficult asthma'' by M. Humbert appeared or will soon appear. These were proposed and edited by JMAs.

                      The collaboration with Allergy will continue as follows:
                      The JMAs propose a title and 2 or 3 alternative authors for a review in the areas where they are interested. The proposal is ranked, as other articles in Allergy are, by a scientific board, and then Allergy's Editor invites one of the proposed authors to submit the review.

                      Another kind of review can be submitted directly by a JMA referring to the theme of his PhD thesis. This review should be written by the JMA in collaboration with his mentor, a Senior Member, and should cover an area linked to the PhD thesis . A short abstract of the review should be submitted and will be subject to the same ranking process mentioned above.

                      We are looking forward for you to send innovative proposals and suggestions at cskevaki@allergy.gr. Also, please do not hesitate to contact me for further questions.

                      On behalf of the JMA Working Group,
                      Chrysanthi Skevaki
                    • JMA-CTA collaboration
                      The JMA Working Group is very pleased to announce a new collaboration with the Clinical and Translational Allergy (CTA) journal (www.ctajournal.com) - the JMA-CTA Collaboration. CTA is the youngest journal in the portfolio of EAACI, exclusively web-based and open-access. CTA welcomes the active involvement of the younger members of the Academy.

                      Key points of the JMA-CTA Collaboration are:
                      • Selection of "Must read papers" for medical residents and other young scientists in the field from each CTA issue. Selected papers will be highlighted by the JMA Logo in the journal's table of contents and appear on our social media websites.
                      • "Hot topic reviews" - JMA have the opportunity to submit 1-A4 page outline proposals to jma@eaaci.org for a review article together with their mentors for publication in the CTA journal. Four selected proposals will be invited to submit a full review which will go through a regular peer-review process. Deadline for submission: 31st July 2014.
                      • Discounts for JMAs - Ten JMAs who publish their original research in CTA will be granted a 50% discount in the article processing charge.
                      • JMA Reviewers - JMAs who are highly active in research and more advanced in their career are strongly encouraged to participate in CTA editorial processes by acting as reviewers. Do not miss the opportunity to express your interest for serving as a reviewer for this journal or to suggest other JMA colleagues! To this end, you may send in a short CV along with a statement of interest and/or your proposals for other possible reviewers to jma@eaaci.org.

                      More details about this collaboration may be found at eaaci.org and in an editorial soon to be published in CTA. Follow us on facebook, twitter and linkedin for regular updates!

                      Why not sign up to receive article alerts from CTA? This will ensure that you are up to date with all of the latest findings published by the journal.

                      Feel free to express your ideas, suggestions and/or comments regarding the establishment of an effective communication between the CTA journal and the JMA community by contacting us at jma@eaaci.org.

                      With our best regards,

                      The JMA-CTA Collaborative Team
                      Alexandra Santos, Valerie Hox, Ibon Eguiluz Gracia, Enrico Heffler (JMA)
                      Clive Grattan, Victoria Cardona, Dimitra Koumaki (CTA)
                    • JMA Quizz
                      Are you an EAACI Junior Member? Don't miss the opportunity to win one of four travel grants for each EAACI Congress with the JMA Quizz.
                      From February to May each year, the JMA WG prepares the JMA Quizz which is made up of five questions each month. These questions can be answered by browsing the EAACI website and topics may include position papers, the structure and activities of EAACI. For each monthly JMA Quizz, EAACI will randomly select a winner among the Juniors who achieved the highest scores to receive a Travel Grant to attend the EAACI Congress. All you have to do is enter your username and password in the indicated link that will appear once the respective JMA Quizz is launched and answer the monthly questions to be in with a chance to win.

                      Follow our official Social Media Accounts: the EAACI JMA Facebook Group, the @EAACI_JMA Twitter and the EAACI JMA Group LinkedIn, and stay tuned to find out more on the launch of each monthly JMA Quizz!

                      JMA Quizz 2014 winners

                      March - Ana-Maria Muresan, Romania
                      April - Elisabetta Calamelli, Italy
                      May – Kassiani Tzeli, Greece (1st winner)
                      May - Ekaterina Khaleva, Russia (2nd winner)
                    • EAACI JMA Educational Game
                      Play the EAACI JMA Educational Game here

                    Latest Educational Resources